Advanced search
Start date

Chlamydomonas reinhardtii as a production platform to obtain biopharmaceuticals of national interest

Grant number: 16/12992-6
Support type:Research Grants - Young Investigators Grants
Duration: November 01, 2017 - October 31, 2021
Field of knowledge:Biological Sciences - Microbiology
Principal Investigator:Lívia Seno Ferreira Camargo
Grantee:Lívia Seno Ferreira Camargo
Home Institution: Centro de Ciências Naturais e Humanas (CCNH). Universidade Federal do ABC (UFABC). Ministério da Educação (Brasil). Santo André , SP, Brazil
Assoc. researchers:João Carlos Monteiro de Carvalho ; Mario Hiroyuki Hirata ; Stephen Mayfield
Associated scholarship(s):19/19308-1 - Evaluation of Chlamydomonas reinhardtii as a production platform of recombinant filgrastime protein, BP.MS
19/13822-5 - Recombinant Somatotropin produced in Chlamydomonas reinhardtii, BP.MS
18/23036-4 - Chlamydomonas reinhardtii recombinant strains cultivation kinetic, BP.IC
17/24486-0 - Chlamydomonas reinhardtii as a production platform to obtain biopharmaceuticals of national interest, BP.JP


The biopharmaceuticals' production and commercialization are directly related to the process scale-up and cost for the entire process up to the final product. This is especially true for complex molecules that are already difficult to produce by using the currently available commercial production platforms. The mammalian cell culture technology, even though produces primarily over 130 commercial therapeutic proteins, it is an expensive production platform due to its complex growth requirements, as well as low protein expression. As the other photosynthetic microorganisms, Chlamydomonas reinhardtii, growth requirements are much simpler and cheaper (salts, light and carbon dioxide). Some of the features for Chlamydomonas as recombinant proteins production platform include: fast generation of stable transformed cell lines, efficient protein folding in non-reducing environment, cell doubling time in about 10h in inorganic media and scalability. The objective of this research is to use Chlamydomonas reinhardtii as a production platform for biopharmaceuticals including some of the ones presented, in 2015, by SUS (Sistema Único de Saúde - Brazilian Public Health System) as products' priorities for Brazil. Proteins with different complexity, expression, accumulation and activity analyses will be evaluated through the techniques of Molecular Biology, western blotting, biomolecules purification, ELISA and cell proliferation assays. The recombinant strains will also be cultivated in a tubular photobioreactor using different light intensities with the purpose of kinetics parameters evaluation, as well as the recombinant protein accumulation during the process cultivation. (AU)